HB1416 would expand the authority of pharmacists in Virginia to initiate treatment, dispense, or administer a broad range of drugs, devices, tests, and supplies under statewide protocols adopted by the Board of Pharmacy in collaboration with the Board of Medicine and the Department of Health. The bill retains existing pharmacist authority for items such as naloxone, epinephrine, contraceptives, prenatal vitamins, fluoride supplements, vaccines, tuberculosis testing, HIV prevention therapies, tobacco cessation products, and certain point-of-care treatments, while adding or clarifying authority for over-the-counter equivalents covered by insurance, COVID-19 and other coronavirus tests, and drugs and devices used to prevent or mitigate influenza symptoms.
A key feature of the bill is its focus on influenza prophylaxis: it expressly authorizes pharmacists to provide drugs and devices for prophylactic purposes to prevent or reduce flu symptoms, and it also allows treatment for influenza infection when guided by a waived clinical test. The bill also permits pharmacist services through telemedicine, subject to existing law and standard-of-care requirements, and includes special provisions for vaccines and COVID-19 testing for persons age 3 and older under a contingent effective date. Pharmacists must notify a patient’s primary care provider when treatment is initiated or a product is dispensed or administered, obtain a relevant patient history, report vaccinations to the state immunization registry, and provide counseling and referrals when patients lack a primary care provider.
The bill would amend § 54.1-3303.1 of the Code of Virginia, expanding and refining the statutory list of pharmacist-initiated treatments and related duties. It would affect pharmacists, patients, insurers, and public health systems by broadening access to preventive care and minor-condition treatment in pharmacy settings, while also imposing documentation, counseling, and reporting requirements. The bill’s insurance-related language could also affect how covered over-the-counter products are selected when the patient’s out-of-pocket cost is lower than buying an equivalent OTC item directly.
The available legislative history suggests limited support in committee. The bill was left in the House Health and Human Services Committee, and a subcommittee recommended striking it from the docket by a 9-0 vote, indicating that it did not advance and faced little visible support at that stage. No committee transcript was provided, so the record does not show detailed debate or negotiated amendments.
The main points of contention appear to be the scope of pharmacist authority and the policy question of whether pharmacists should be able to initiate treatment for a wide range of conditions, including influenza prophylaxis, without a physician visit. Potential concerns likely include patient safety, appropriate screening and follow-up, the boundaries of pharmacist practice, and the administrative burden of notification and reporting requirements. Supporters would likely emphasize improved access, convenience, and earlier treatment, especially for common infectious diseases and preventive services.
HB1416 would expand § 54.1-3303.1 of the Code of Virginia by adding influenza prophylaxis to the list of pharmacist-initiated treatments and by clarifying pharmacist authority to provide certain tests, drugs, and devices under statewide protocols. It would also reinforce existing duties for patient screening, provider notification, immunization reporting, counseling, and telemedicine-based service delivery, affecting pharmacists, patients, and related health-care providers and insurers.
The bill appears to have had weak support in committee. It was left in the House Health and Human Services Committee, and a subcommittee recommended striking it from the docket on a 9-0 vote. With no transcript available, the record suggests little momentum and no visible opposition recorded in the vote history, but the outcome indicates the proposal did not gain traction.
The likely areas of contention are the breadth of pharmacist prescribing authority, especially for influenza prophylaxis and other condition-based treatment, and whether pharmacists should be authorized to initiate care that may otherwise be handled by physicians or other prescribers. Additional concerns may include patient safety screening, follow-up care, reporting obligations, and the extent to which telemedicine should be used for these services. Support would likely come from those favoring expanded access to care and convenience, while skepticism would likely come from those concerned about scope-of-practice expansion and clinical oversight.